Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) fell 4.5% on Tuesday . The company traded as low as $28.59 and last traded at $28.6750. 176,375 shares traded hands during trading, a decline of 92% from the average session volume of 2,123,972 shares. The stock had previously closed at $30.04.
Wall Street Analyst Weigh In
CAPR has been the subject of a number of recent research reports. UBS Group set a $50.00 target price on shares of Capricor Therapeutics in a report on Monday, December 15th. Piper Sandler reaffirmed an "overweight" rating and issued a $45.00 price objective (up previously from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Oppenheimer increased their target price on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an "outperform" rating in a research report on Monday, December 8th. B. Riley restated a "buy" rating and issued a $50.00 target price (up from $21.00) on shares of Capricor Therapeutics in a research note on Monday, December 15th. Finally, Alliance Global Partners reaffirmed a "buy" rating on shares of Capricor Therapeutics in a research report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $40.82.
Read Our Latest Analysis on Capricor Therapeutics
Capricor Therapeutics Trading Down 3.3%
The company has a market cap of $1.33 billion, a PE ratio of -16.07 and a beta of 0.62. The firm's 50-day simple moving average is $14.25 and its two-hundred day simple moving average is $10.04.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.54). As a group, analysts predict that Capricor Therapeutics, Inc. will post -1.21 EPS for the current year.
Institutional Trading of Capricor Therapeutics
Several large investors have recently made changes to their positions in CAPR. Voleon Capital Management LP acquired a new position in shares of Capricor Therapeutics during the 3rd quarter worth approximately $311,000. Moneta Group Investment Advisors LLC grew its stake in Capricor Therapeutics by 25.5% in the 3rd quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company's stock valued at $248,000 after acquiring an additional 7,000 shares during the period. Brevan Howard Capital Management LP purchased a new stake in Capricor Therapeutics in the 3rd quarter worth $123,000. Raymond James Financial Inc. raised its position in Capricor Therapeutics by 1,629.9% during the third quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company's stock worth $1,379,000 after acquiring an additional 180,234 shares during the period. Finally, Brooklyn Investment Group acquired a new position in Capricor Therapeutics during the third quarter worth $274,000. 21.68% of the stock is owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here

We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.